· In both cohorts, most cases of CRS and CAR-T cell neurotoxicity resolved - Cohort A: 19/19 CRS cases, 3/3 ICANS cases, and 2/3 other neurotoxicity cases resolved - Cohort B: 16/16 CRS cases, 1/1 ICANS case, and 3/5 other neurotoxicity cases resolved